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Abstract. As of October 2012 84 countries had re-
ported at least 1 case of extensively drug resistant tubercu-
losis (EDR TB). In November 2012, the WHO epidemiol-
ogical surveillance stated: all new TB cases in the world are 
3,7 % of multi-drug resistant tuberculosis (MDR TB); 
60,0 % of MDR TB among the new cases of TB are docu-
mented in Brazil, China, India, and South Africa. 
Key words: tuberculosis, multi-drug resistant tuber-
culosis, fluoroquinolones, malabsorption syndrome. 
Introduction. Pathology of the gastrointestinal 
tract (GI) ranks the third place on comorbidity in 
patients with lung tuberculosis (LTB). As early as in 
the late XIX century the notion of "pretuberculosis 
dyspepsia” emerged [4, 7]. It was due to the fact that 
in some of patients with an unclear diagnosis, who 
complained of steady loss of appetite, weight loss, 
discomfort in the epigastric region, and had been 
visiting a doctor for years, pulmonary tuberculosis 
was revealed later on [1, 8]. 
A significant incidence of comorbidity is ex-
plained not only by related pathogenetic factors of 
diseases, but by adverse effects of drugs on the gastro-
intestinal tract in patients with LTB, the spread among 
the latter, burdened with social and behavioral factors 
[2, 5]. One of the reasons for inefficient treatment in 
LTB is malabsorption of anti-TB drugs taken per os, 
which causes insufficient drug concentrations in 
blood and lesions, which favour development of 
chemoresistant TB [1, 8]. Excessively expressed syn-
drome of the systemic inflammatory response in TBL 
contributes to the development of a malabsorption 
syndrome [1, 6, 8]. So, to resolve the problem of ef-
fective treatment a parenteral route of administration 
of anti-TB medicines should be recommended for 
patients with TB and gastrointestinal comorbidity.  
Aim: to evaluate the clinical efficacy of oral 
and intravenous anti-TB treatment in the intensive 
phase of chemotherapy (IFHT) in patients with pul-
monary MDR TB.  
73 patients were included in the open-label ran-
domized study (74,3 % male, 25,7 % female) aged 
20 to 76 years. Criteria – patients with newly diag-
nosed pulmonary MDR TB.  
Materials and Methods: clinical, laboratory, 
X-ray, microscopy, microbiology, statistics. 
We compared the efficacy of oral and injectable 
fluoroquinolones in patients with MDR TB. 
Levofloxacin (Lfx) – tablet form was used in 43,9 % 
of patients, injectable form – in 40,4 % (Leflocin by 
"Yuria-Pharm“, Ukraine); moxifloxacin (Mfx) – 
(Maxicin by "Yuria-Pharm“, Ukraine) in 8,8 % of 
patients; gatifloxacin (Gfx) – (Bigaflon by "Yuria-
Pharm“, Ukraine) in 7,0 % of patients. 
All patients included in the study by selection of 
pairs in form prevalence of tuberculosis process and 
the severity were divided into four groups.  
I – 25 patients. In IFHT Lfх was used in a dose 
of 1000 mg orally for 8 months; II – 23 patients. In 
IFHT Lfх was used intravenously – 1000 mg per day 
for a month. And then 1000 mg – orally for 7 
months; III – 11 patients. In IFHT Mfx was applied 
intravenously (infusion concentrate of 20 mg/ml) 
400 mg per day for a month (does not require dose 
adjustment in patients with impaired liver and kidney 
function), followed oral intake of 400 mg for 7 
months; IV – 14 patients. In IFHT Gfx 400 mg 
(infusion solution 0,4 % 200 mL) was applied intra-
venously per day for a month. Then orally 400 mg 
for blisters for 7 months.  
Results and discussion. While analyzing the 
effectiveness of chemotherapy in tablet and injection 
forms Lfx (in a month) sputum microscopy results 
showed, that sputum conversion in group I took 
place in 20 % and in patients of group II – in 37,3 % 
(p<0,05). Normalization of complete blood count in 
group I was recorded in 24,0 % of patients, in group 
II – in 34,8 % respectively (p<0,05). The absence of 










Sputum conversion healing foci of
infection
cavities healing blood clinics
oral IV
Fig. 1. Analysis of the effectiveness of chemotherapy in tablet and injectable forms Lfx (in 1 month) 
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major clinical manifestations of tuberculosis in group 
1 was observed in 36,0 % of cases and in group II – 
in 52,2 %, respectively (p<0,05).  
Thus, studies have confirmed the higher effi-
ciency of the use in an intensive phase (one month) 
of chemotherapy programs for MDR TB patients 
injectable Lfх versus tablet form. Intergroup value of 
indicators is different significantly, р=0,01. 
Individual modes of antimycotic therapy for 
patients of groups II, III and IV were formed accord-
ing to drug sensitivity test (ВАСТЕС method) [3]. 
Assessment of individual chemotherapy regi-
mens for clinical and laboratory parameters was per-
formed a month after the use of injectable fluoroqui-
nolones of the 3rd and 4th generations (Lfx, Gfx and 
Mfx). 
Analysis of the data in dynamics showed, that at 
prescription of Mfx in regimes of chemotherapy 
(after a month) cessation of bacterial excretion was 
observed in 62,7 % of patients, Gfx – in 59,1 %, Lfl 
– in 37,3 % respectively. Normalization of complete 
blood analysis in groups II, III and IV after a month 
of treatment was in 34,8 %, 35,8 % and 37,9 % re-
spectively. Absence of main clinical manifestations 
after a month of treatment at prescription of Lfx was 
observed in 52,2 % of cases, Gfx – in 57,9 %, Mfx – 
in 59,2 % respectively. 
The effectiveness of different programs with 
using fluoroquinolones of the 3rd and 4th genera-
tions (1 month) at the end of the intensive chemo-
therapy phase: efficacy in gr. II was 90 %: in gr. 3 – 
98,2 %; in gr. 4 – 97,1 % due to the high percentage 
of complete resorption of focal infiltrative changes 
and cavities healing, which are epidemiologically 
important indicators for monitoring the spread of 
tuberculosis infection. 
In the comparative analysis of the efficiency of 
injectable fluoroquinolones of the 3rd and 4th gen-
erations in patients with MRTB the fourth generation 
demonstrated significantly higher efficacy.  
Thus, benefits of injectable administration of 
anti-TB drugs: 100 % bioavailability, quick achiev-
ing high concentrations of the drug in the lesion fo-
cus, regardless of the state of the digestive tract, the 
characteristics of the diet and comorbidities, reduc-
ing the number of side effects, possibility to intensify 
treatment, reduction of cases of therapy interruption 
(100% control), accurate dosing. 
Conclusions 
1. Malabsorption syndrome is a common co-
morbid condition in most tuberculosis patients. Thus, 
studies have confirmed the higher efficiency of the 
use in an intensive phase (one month) of chemother-
apy programs for MDR TB patients injectable Lfх 
versus tablet form. Intergroup value of indicators is 
different significantly, р=0,01. Intravenous introduc-
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tion of anti-TB chemotherapy is recommended in all 
tuberculosis patients with poor absorption. 
2. The comparative analysis of the efficiency of 
treatment at prescription of injecting fluoroqui-
nolones of the 3rd and 4th generations in group 2 is 
90 %, in the group 3 – 98,2 % in group 4 – 97,1 %, 
due to the high percentage of complete resorption of 
focal infiltrative changes and scarring decay cavities 
that are epidemiologically important indicators for 
monitoring the spread of tuberculosis infection. 
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СИНДРОМ МАЛЬАБСОРБЦИИ КАК ПРОЯВЛЕНИЕ СИСТЕМНОГО ЭФФЕКТА  
ПРИ РАСПРОСТРАНЕННЫХ ФОРМАХ ТУБЕРКУЛЕЗА ЛЕГКИХ 
Л.Д. Тодорико, И.В. Еременчук, В.П. Шаповалов, Т.И. Ильчишен 
Резюме. По состоянию на октябрь 2012 года 84 страны мира сообщили хотя бы об одном случае туберкулеза с 
расширенной резистентностью (РРТБ). В ноябре 2012 года эпиднадзор ВОЗ констатировал: среди всех новых слу-
чаев туберкулеза в мире 3,7 % это мультирезистентный туберкулез (МРТБ); 60,0 % случаев МРТБ в мире установ-
лено в Бразилии, Китае, Индии и Южной Африке. 
Ключевые слова: туберкулез, мультирезистентный туберкулез, фторхинолоны, синдром мальабсорбции. 
СИНДРОМ МАЛЬАБСОРБЦІЇ ЯК ПРОЯВ СИСТЕМНОГО ЕФЕКТУ  
ПРИ ПОШИРЕНИХ ФОРМАХ ТУБЕРКУЛЬОЗУ ЛЕГЕНЬ 
Л.Д. Тодоріко, І.В. Єременчук, В.П. Шаповалов, Т.І. Ільчишен  
Резюме. Станом на жовтень 2012 року 84 країни світу повідомили хоча б про один випадок туберкульозу із 
розширеною резистентністю (РРТБ). У листопаді 2012 року епіднагляд ВООЗ констатував: серед усіх нових випад-
ків туберкульозу у світі 3,7 % це мультирезистентний туберкульоз (МРТБ); 60,0 %  випадків МРТБ у світі установ-
лено в Бразилії, Китаї, Індії, та Південній Африці.  
Ключові слова: туберкульоз, мультирезистентний туберкульоз, фторхінолони, синдром мальабсорбції.  
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